| Literature DB >> 20617050 |
Silke B Wolfenstetter1, Christina M Wenig.
Abstract
This systematic review aims to assess the characteristics of, and the clinical and economic evidence provided by, economic evaluations of primary preventive physical exercise interventions, and to analyse their transferability to Germany using recommended checklists. Fifteen economic evaluations from seven different countries met eligibility criteria, with seven of the fifteen providing high economic evidence in the special country context. Most of the identified studies conclude that the investigated intervention provide good value for money compared with alternatives. However, this review shows a high variability of the costing methods between the studies, which limits comparability, generalisability and transferability of the results.Entities:
Keywords: cost-effectiveness; cost-utility; economic evaluation; physical activity intervention; primary prevention; transferability
Mesh:
Year: 2010 PMID: 20617050 PMCID: PMC2872359 DOI: 10.3390/ijerph7041622
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Figure 1.Flow of information through the different phases of the systematic review according to PRISMA guidelines [23].
Study characteristics and key findings.
| Author (year published) [Ref.] | Study design/Type of EconA | Type of physical exercise intervention/alternative/length of intervention | Outcomes | Study Population: n/age (range or mean)/exclusion and/or inclusion criteria | Country/setting/year of study | Economic key findings | EURO conversion (2008) | Clin. |
|---|---|---|---|---|---|---|---|---|
| Dzator | RCT/CEA | Self-directed intervention of PA and nutrition delivered by mail (low level) or by mail and group sessions (high level)/no intervention/16 weeks | Change in BMI, total and HDL cholesterol, blood pressure, PA (W/kg), nutrition fat intake | 137 couples/all ages/IN: cohabitation for the first time, living together for < 2 years, no pregnancy for length of study/EX: CHD, severe asthma, diabetes | Australia/ home/ n.s. | 1-year follow up: Average incremental costs/unit change in outcome variables:1) high intervention: AUD460; 2) low intervention: AUD459; 3) control: AUD462 | No year of intervention | 1+/m |
| Elley | Cluster RCT/CEA | Green Prescription: verbal and written exercise advice by GP and telephone exercise specialist/usual care/1 year | Total energy expended (change in PA), QALY | 878/40-79 years/IN: less active (<2.5 hours of moderate activity per week) | New Zealand/ GPP/ 2000–2002 | 1) Monthly CER: NZD11/kcal/kg/day; 2) ICER: NZD1,756/ converted sedentary adult to an active state in 12 months | 1) €8; | 1−/h |
| Finkelstein | RCT/CEA | WISEWOMAN Project: screening and counselling (e.g., walking, dance, chair-aerobics, weight training)/MI | Risk of CHD, LYG | 1586 women/40–64 years/IN: uninsured or underinsured with low annual income/take part in NBCCED-programme | USA/ community and healthcare sites/1996 | 1) IC of EI per person: USD191; 2) ICER: USD637/ 1%point additional decrease in 10 year probability of CHD for EI compared with MI; 3) nearly USD5,000/ LYG (n.sig.) | Apy (1996): 1) €226; | 1−/m |
| Robertson | RCT/CEA | Otago: Individually home-based PA by district nurse/usual care/1 year | Falls and injuries | 240/≥75 years/invited by GP/EX: abasia, receiving physiotherapy | New Zealand/ GPP/ 1998 | 1) ICER: NZD1,803/ fall prevented; 2) NZD7,471/ injurious fall prevented (cost saving for people older than 80 years) | 1) €1,423; | 1+/h |
| Robertson | CT/CEA | Otago: Individually home-based PA by general practicenurse/usualcare/1 year | Falls and injuries | 450/≥80 years/invited by GP/EX: abasia, receiving physiotherapy | New Zealand/ GPP/ 1998 | 1) ICER: NZD1,519/ fall prevented;2) NZD3,404/ injurious fall prevented | 1) €1,202;2)€2,694; | 2+/h |
| Robertson | RCT/CEA | Otago: Individually home-based PA by physiotherapist/usual care/2 years | Falls and injuries | 233 women/≥80 years/invited by GP/EX: abasia, receiving physiotherapy | New Zealand/ GPP, home/ 1995–1997 | 1) ICER: NZD314/ fall prevented (1 year); NZD265/ fall prevented (2 years) 2) NZD457/ injurious fall prevented (1year); NZD 426/ injurious fall prevented (2 years) | 1) €261; €220 | 1+/h |
| Stevens | RCT/CEA | Individual PA by exercise development officer/ EI vs MI/10 weeks | PA, number of sedentary people | 714 participants/45–74 years/four subgroups (sedentary, low/high intermediate, active)/2 GPP/EX: disabled, CHD | UK/GPP/n.s. | 1) £623/ one sedentary person doing more PA; 2) £2,498/ moving someone who is active but below min level | No year of intervention | 1+/m |
| The Writing Group (2001) [ | RCT/costs, effects (CEA) | PA counselling with current recommended care/usual care/2 years | Cardio-respiratory fitness, self-reported PA | 874/35–75 years/IN: inactive, in primary care, in stable health, EX: chronic diseases, CHD | USA/GPP/ 1995–1997 | 1) For 2 years: IC/ participant of assistance intervention: USD500; 2) IC of counselling intervention/ participant: USD1,100 | Apy (1996): 1) €591; | 1++/l |
| Proper | RCT/CBA, CEA | Worksite PA counselling/EI | Sick leave, PA, cardiovascular fitness | 299/44 years/IN: civil servants from three municipal services, performing office work at least 24 hours a week | Netherlands/ municipal services/ 2000–2001 | CER without (with) imputation of effect data: 1) €5 (€3)/ extra energy expenditure (kcal/day); 2) €235 (€46)/ beat per minute of decrease in submaximale heart rate; 3) total net costs (9 months): €305; 4) benefits from sick leave reduction (1 year later): €635 | Apy (2000): 1) €6 (€3); | 1+/m |
| Shepard (1992) [ | CT/CBA, CEA | Employee fitness programme (rhythmic, aerobic type activity, stretching, cardio-respiratory activity)/no intervention/12 years | PA, absenteeism, corporate commitment | 534/age n.s./office workers of two major insurance companies | Canada/ company/ 1977–1990 | 1) Programme benefits/worker/year (participation rate of 20%): CAD679; 2) ROI: CAD7; 3) Cost-benefit: CAD5 to 1 | 1) €757; | 2-/l |
| Chen | Cluster RCT/CUA | Walking/no intervention/12 weeks | Health service utilisation, QALY | 98/>65 years | Taiwan/community/n.s. | ICER: USD15,103/ QALY gained | No year of intervention | 1−/m |
| Dalziel/ Segal (2006) [ | Cluster RCT/CUA (Markov Model) | Green Prescription: verbal and written exercise advice by GP and telephone exercise specialist/usual care/1 year | Lifestyle change, activity change, QALYs | 878/40–79 years/42 GPP/IN: less active | New Zealand/ GPP/ 2000–2002 | ICER: NZD2,053/ QALY gained (lifetime) | €1,483 | 1−/m |
| Lindgren | RCT/CEA, CUA (Markov Model) | Dietary advice by dietician and exercise instructions by physician/usual care/18 months | Physiological factors, QALYs, LYG | 813 men/60 years/EX: CHD, diabetes, severe illness, no cholesterol, regular use of drugs | Sweden/ community/ 1992 | ICER (declining effect of intervention): 1) Diet: SEK127,065/ LYG (SEK130,505/ QALY gained); 2) Exercise: SEK180,470/ LYG (SEK191,750/ QALY gained); 3) Exercise+diet: SEK201,375/ LYG (SEK201,375/ QALY gained) | 1) €15,274 (€15,687); | 1+/h |
| Munro | Cluster RCT/CUA | Free exercise classes (e.g., bowling, swimming, country walking, and tea dances) by qualified exercise leader/usual care/2 years | Mortality, hospital service use, health status, QALY | 6420/>65 years/EX: PA score in the top 20%, patients who were unsuitable for exercise | UK/ community/ 2003–2004 | ICER: €17,172/ QALY gained | ICER: €18,364 | 1−/h |
| Sims | Cluster RCT/CEA, CUA (Model) | Active Script Programme (ASP): training and support of GPs who deliver advice on PA/usual care/2 years | Number of advising GPs, patients becoming active or accruing health benefit, DALYs/deaths averted | 670 GPs/practice population/20–75 years, sedentary | Australia/ GPP/ community/ 1999–2000, 2000–2001 | 1) AUD69/ patient to become more active (short term); 2) AUD138/ patient to accrue a health benefit; 3) AUD3,647/ DALY saved; 4) AUD48,924/ premature death averted | 1) €62; | 1−/h |
(1++) High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias; (1+) High quality meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias; (1–) High quality meta-analyses, systematic reviews of RCTs, or RCTs with a high risk of bias; (2+) Well-conducted case-control, before-after studies or cohort studies with a low risk of confounding, bias or change and a moderate probability that the relationship is causal. (2–) Case-control, before-after studies or cohort studies with a high risk of confounding, bias or change and a high risk that the relationship is not causal. [28]
h = high; l = low; m = moderate. Abbreviations: ASP: Active Script Programme; apy: Assumed price year; BMI: Body-mass-index; CHD: Cardiovascular heart disease; CG: Control Group; CT: Controlled trial; CBA: Cost benefit analysis; CE: Cost-effectiveness; CEA: Cost-effectiveness analysis; CER: Cost-effectiveness ratio; CUA: Cost utility analysis; DALY: Disability adjusted life years; EconA: Economic analysis; EI: Enhanced intervention; EX: Exclusion criteria; GP: General practitioner; GPP: General practitioner practices; HDL: High Density Lipoprotein; IN: Inclusion criteria; ICER: Incremental cost-effectiveness ratio; IG: Intervention Group; kcal: Kilocalorie; LYG: Life years gained; MI: Minimum intervention; NBCCED: National Breast and Cervical Cancer Early Detection; NB: Net benefit; n.s.: not stated; PA: Physical activity; QALY: Quality adjusted life year; RCT: Randomised controlled trial; ROI: Return on investment; SEK: Swedish Krona; W/kg: Watt/kilogram.
Evaluation of economic evidence according to CHEC-List by Evers et al. (2005)1.
| Is the study clearly described? | Are competing alternatives clearly described? | Is a well-defined research question posed in answerable form? | Is the economic study design appropriate to the stated objective? | Is the chosen time horizon appropriate in order to include relevant costs and consequences? | Is the actual perspective chosen appropriate? | Are all important and relevant costs for each alternative identified? | Are all costs measured appropriately in physical units? | Are costs valued appropriately? | Are all important and relevant outcomes for each alternative identified? | Are all outcomes measured appropriately? | Are outcomes valued appropriately`? | Is an incremental analysis of costs and outcomes for each alternative performed? | Are all future costs and outcomes discounted appropriately? | Are all important variables, whose values are uncertain, appropriately subjected to sensitivity analysis? | Do the conclusions follow from the data reported? | Does the study discuss the generalisability of the results to other settings and patient/ client groups? | Does the article indicate that there is no potential conflict of study researcher(s) and funder(s)? | Are ethical and distributional issues discussed appropriately? | Economic evidence | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 0,5 | 1,0 | 1,0 | 1,0 | 0,5 | 0,0 | 0,5 | 0,0 | 0,5 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 0,0 | ||
| 1,0 | 0,5 | 1,0 | 1,0 | 0,5 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 0,5 | 1,0 | 0,0 | ||
| 1,0 | 0,5 | 1,0 | 1,0 | 0,5 | 0,0 | 0,5 | 0,0 | 0,5 | 1,0 | 0,5 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 0,5 | 1,0 | 1,0 | ||
| 1,0 | 1,0 | 1,0 | 1,0 | 0,5 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 0,0 | ||
| 1,0 | 1,0 | 1,0 | 1,0 | 0,5 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 0,5 | 1,0 | 0,0 | ||
| 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 0,0 | 1,0 | 1,0 | 1,0 | 1,0 | 0,0 | ||
| 1,0 | 1,0 | 1,0 | 0,5 | 0,0 | 0,0 | 0,0 | 0,0 | 0,0 | 1,0 | 1,0 | 1,0 | 0,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 0,0 | ||
| 1,0 | 1,0 | 0,5 | 0,0 | 1,0 | 0,0 | 0,0 | 0,0 | 0,0 | 1,0 | 1,0 | 1,0 | 1,0 | 0,0 | 0,0 | 0,5 | 0,0 | 1,0 | 0,0 | ||
| 1,0 | 1,0 | 0,5 | 1,0 | 0,0 | 0,5 | 1,0 | 0,0 | 0,5 | 1,0 | 1,0 | 0,5 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 0,0 | ||
| 0,5 | 0,5 | 0,5 | 1,0 | 1,0 | 0,0 | 0,5 | 0,5 | 0,5 | 1,0 | 0,5 | 0,5 | 0,0 | 0,0 | 0,0 | 1,0 | 0,5 | 0,0 | 1,0 | ||
| 1,0 | 1,0 | 1,0 | 1,0 | 0,0 | 0,0 | 1,0 | 0,0 | 0,5 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 0,0 | 1,0 | 0,5 | 1,0 | 1,0 | ||
| 1,0 | 0,5 | 1,0 | 1,0 | 1,0 | 0,5 | 0,5 | 0,5 | 0,5 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 0,5 | 1,0 | 1,0 | 0,0 | ||
| 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 0,5 | 0,5 | 0,5 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 0,5 | 0,5 | 1,0 | 0,0 | ||
| 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 0,5 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 0,0 | 1,0 | 1,0 | 0,5 | 1,0 | 0,0 | ||
| 0,5 | 1,0 | 1,0 | 1,0 | 1,0 | 0,5 | 1,0 | 0,5 | 0,5 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 1,0 | 0,5 | 1,0 | 0,0 |
Asessment: Yes = 1; No = 0; Unclear= 0,5; Economic evidence grade: 0–0.50 = low; >0.50–0.80= moderate/limited; >0.80–1= high;
<1year = 0; 1–<2 years = 0.5; >2 years = 1;
The valuation of the reviewed studies without discounting was calculated with 1 if the evaluation period was less than 18 months and 0 if the time horizon was more than 18 months.
Limitations of transferability of economic evaluation results according to Welte et al. (2004) 1 [35].
| Dzator | duration of the intervention relatively short (16 weeks); higher economic status was over-represented in the study (potential bias); responders more motivated than non responders (selection bias); perspective not stated; only costs were discounted; price year not stated; high clinical and moderate economic evidence |
| Elley | control group may have taken part in exercise trial (potential bias); 1/3 of eligible participants did not participate (selection bias); large 95%CIs and imprecision around changes in major offset costs, especially healthcare utilisation costs and productivity costs (an overall cost-effectiveness from societal perspective could not be calculated); only costs were discounted; moderate clinical and high economic evidence |
| Finkelstein | baseline comparability of two groups not discussed; uninsured, low income women (US specific sample); no control group with no intervention; no discussion about women not taking part in interventions; no sensitivity analysis; perspective not stated; costs for single unit are not stated; price year not stated; only effects discounted; moderate clinical and moderate economic evidence |
| Robertson | district nurse (potential instructor bias); only cost-saving for people older than 80 years; costs could be different in an urban area (e.g., less transport costs); high clinical and high economic evidence |
| Robertson | general practice nurse (potential instructor bias); costs could be different in an urban area (e.g., less transport costs); no randomisation; moderate clinical and high economic evidence |
| Robertson | research physiotherapist (potential instructor bias); costs could be different in an urban area (e.g., less transport costs); no discounting; high clinical and high economic evidence |
| Stevens | perspective not stated; no explanation for choice of comparator; no data on effectiveness; exercise development officer (potential therapist bias); short intervention time (10 weeks); unit costs could be halved with a better recruitment strategy; ICER not stated; perspective not stated; physical units not stated; no discount rate; price year not stated; valuation of the costs not mentioned; high clinical and moderate economic evidence |
| The Writing Group (2001) [ | only effects are differentiated; not significantly effective for men; perspective not stated; discount rate not stated; physical units not stated; sensitivity analysis not stated; cost measurement and valuation not stated; high clinical and low economic evidence |
| Proper | large CIs of CE-Ratios (not statistical significant);health care costs only accountable by municipal service; underpowered trial= 94–167; potential other benefits excluded like employer turnover, productivity, commitment; CBA is a CEA (no monetary valuing of the benefits); price year not stated; physical units not stated; high clinical and moderate economic evidence |
| Shepard (1992) [ | costs not stated explicitly; study years not stated appropriately; no randomisation of the study population; not all items of programme costs calculated; CEA and CBA are not explained adequately; no further description of the target population; ICER not stated; perspective not stated; no discounting; physical units not clearly stated; sensitivity analysis not stated; moderate clinical and low economic evidence |
| Chen | perspective not stated; physical units not stated; no sensitivity analyses; short time horizon; valuation of utilisation not stated; only programme costs included; high clinical and moderate economic evidence |
| Lindgren P | only 60 year old men - transferability to other ages unclear; Markov Model uses risk factors taken from Framingham (calculated for UK and Germany); only Human Capital approach; Physical activity programme not described; high clinical and high economic evidence |
| Dalziel K, Segal L (2006) [ | based on many assumptions; wide range of ICER; short follow up period in the primary clinical trial (Elley |
| Munro | SF-36 non responders were assumed having no health benefit; benefit by participants in exercise programmes greater than the suggests (potential selection bias); exclusion of the top 20% (selection bias); participation rate and levels of missing data are correlated; low recruitment rate; follow-up period too short for mortality and admission rates; no discounting; moderate clinical and high economic evidence |
| Sims J | method of discounting not explained; model and costs not described in detail; no indirect costs; percentage of patients to become active assumed; moderate clinical and high economic evidence |
Abbreviations: CBA: Cost-benefit analysis; CE: Cost-effectiveness; CEA: Cost-effectiveness analysis; ICER: Incremental cost-effectiveness ratio; CI: Confidence interval; UK: United Kingdom; US: United States.